DPIIT recognised startup Government of India
Startup India
Market Cap
₹214 Cr
ANL · BSE
Share Price
₹273.10
-7.42% today
Revenue
₹33.60 Cr
FY 2025-26 · +110.0% YoY
EBITDA
₹6.89 Cr
Margin 20.5%
Net Profit
₹5.07 Cr
FY 2025-26 · +102.0% YoY
ROE
25.0%
ROCE 27.7%
Debt / Equity
0.20
Interest cover 8.0x
Authorised capital
₹8 Cr
Registered with MCA
About Accretion Nutraveda Limited
Data last updated:
Accretion Nutraveda Limited is a public limited company based in Ahmedabad, Gujarat, India, recognised as a startup by DPIIT. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 16 March 2021 and has been in existence for over 5 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN U24290GJ2021PLC121216. Its GSTIN is 24AAUCA9884F1Z0 (Gujarat). It is a listed company as per MCA records. Its shares are listed on BSE: 544694.
The company has an authorised share capital of ₹8 Cr and a paid-up capital of ₹5.32 Cr. It is led by directors including Mayur Popatlal Sojitra (Managing Director) and Ankurkumar Shantilal Patel (Whole-Time Director).
Its last annual general meeting (AGM) was held on 11 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 27 Xcelon Industrial Park – 1 Vasna – Chacharwadi Ta – Sanand, Ahmedabad, Gujarat, India – 382213.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹33.6 Cr, a growth of 110% compared to the previous year. For the same year it recorded a net profit of ₹5.07 Cr (net margin 15.1%) and EBITDA of ₹6.89 Cr (EBITDA margin 20.5%). The net worth stands at ₹35.47 Cr (up 602.4% YoY). Total assets are valued at ₹39.7 Cr (up 345.6% YoY).
The company is associated with 1 brand: Accretion Pharmaceuticals. As per MCA filings, the company has open charges of ₹3.46 Cr on record. The company has 6 deals on record (5 market trades, 1 ipo); the latest was in September 2026.
Accretion Nutraveda Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-01-0063345). For more details, the company can be reached via its website accretionpharma.com.
Company details
CIN U24290GJ2021PLC121216
Registration Number 121216
Incorporation Date 16 March 2021
ROC Ahmedabad
Listing Status Listed - Listed on BSE (544694)
Company Status Active
Date of Last AGM 11 September 2025
Date of Balance Sheet 31 March 2026
DPIIT Recognition Recognised Startup
MSME Classification Small
Udyam Registration UDYAM-GJ-01-0063345
CIN history
Accretion Nutraveda has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24290GJ2021PLC121216, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24290GJ2021PLC121216 | Current |
| U24290GJ2021PTC121216 | Previous |
| L24290GJ2021PLC121216 | Previous |
Key People
Mayur Popatlal Sojitra Managing Director Ankurkumar Shantilal Patel Whole-Time Director Paraskumar Vinubhai Parmar Cfo Recognitions & Rankings of Accretion Nutraveda
MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-GJ-01-0063345
Contact details
Accretion Nutraveda Limited's registered office is in Ahmedabad, Gujarat.
- Registered Address27 Xcelon Industrial Park – 1 Vasna – Chacharwadi Ta – Sanand, Ahmedabad, Gujarat, India – 382213
- IndustryPharma, Drug Formulation & Development
Comprehensive company report
Accretion Nutraveda Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Accretion Nutraveda operates one associated brand: Accretion Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Tablets, capsules, and oral liquids are manufactured for therapeutic categories. | accretionpharma.com |
Financials of Accretion Nutraveda Limited
FY 2025-26 filings availableAccretion Nutraveda Limited reported revenue of ₹33.6 Cr (up 110% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹33.60 Cr
+110.0% YoY
EBITDA
₹6.89 Cr
+85.2% YoY
Profit After Tax
₹5.07 Cr
+102.0% YoY
Net Worth
₹35.47 Cr
+602.4% YoY
Total Assets
₹39.70 Cr
+345.6% YoY
Total Debt
₹4.23 Cr
+9.6% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 33.60 | 16.00 | 5.01 | 2.90 |
| Revenue growth | +110.0% | +219.4% | +72.8% | - |
| EBITDA | 6.89 | 3.72 | 1.23 | 0.62 |
| EBITDA margin | +20.5% | +23.3% | +24.6% | +21.4% |
| Profit before tax | 6.21 | 3.16 | 0.92 | 0.29 |
| Net profit | 5.07 | 2.51 | 0.83 | 0.28 |
| Net profit margin | +15.1% | +15.7% | +16.6% | +9.7% |
| EPS (₹) | 7.00 | 51.35 | 22.83 | 7.79 |
| Balance sheet | ||||
| Total assets | 39.70 | 8.91 | 3.26 | 2.24 |
| Net worth | 35.47 | 5.05 | 1.08 | 0.26 |
| Total debt | 4.23 | 3.86 | 2.17 | 1.97 |
| Cash & bank | 9.74 | 0.02 | 0.12 | 0.09 |
| Net working capital | 28.18 | 7.07 | 1.89 | 0.78 |
| Cash flow | ||||
| Cash from operations | (9.42) | (2.22) | 0.23 | 0.68 |
| Cash from investing | (14.50) | (0.87) | (0.16) | (0.01) |
| Cash from financing | 25.19 | 2.98 | (0.04) | (0.63) |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Revenue | 33.60 | 16.00 | 5.01 | 2.90 |
| Revenue growth | +110.0% | +219.4% | +72.8% | - |
| Other income | 0.11 | 0.01 | 0.19 | 0.17 |
| Total expenses | 26.71 | 12.28 | 3.78 | 2.28 |
| Employee cost | 0.50 | 0.23 | 0.18 | 0.10 |
| EBITDA | 6.89 | 3.72 | 1.23 | 0.62 |
| EBITDA margin | +20.5% | +23.3% | +24.6% | +21.4% |
| Depreciation | 0.26 | 0.22 | 0.26 | 0.31 |
| Interest | 0.53 | 0.35 | 0.24 | 0.19 |
| Profit before tax | 6.21 | 3.16 | 0.92 | 0.29 |
| Tax | 1.14 | 0.65 | 0.09 | 0.01 |
| Net profit | 5.07 | 2.51 | 0.83 | 0.28 |
| Net profit margin | +15.1% | +15.7% | +16.6% | +9.7% |
| EPS (₹) | 7.00 | 51.35 | 22.83 | 7.79 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Equity & liabilities | ||||
| Share capital | 7.24 | 0.49 | 0.36 | 0.36 |
| Reserves & surplus | 28.23 | 4.56 | 0.72 | (0.10) |
| Shareholders' funds (net worth) | 35.47 | 5.05 | 1.08 | 0.26 |
| Secured loans | 0.36 | 1.93 | 1.42 | 1.30 |
| Unsecured loans | 3.87 | 1.93 | 0.75 | 0.67 |
| Total debt | 4.23 | 3.86 | 2.17 | 1.97 |
| Total liabilities | 39.70 | 8.91 | 3.26 | 2.24 |
| Assets | ||||
| Gross block | 2.86 | 2.78 | 2.03 | 1.97 |
| Net block | 1.65 | 1.83 | 1.28 | 1.49 |
| Capital work in progress | 0.00 | 0.00 | 0.10 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 8.99 | 4.59 | 2.38 | 1.30 |
| Sundry debtors | 8.11 | 3.27 | 0.25 | 0.80 |
| Cash & bank balances | 9.74 | 0.02 | 0.12 | 0.09 |
| Loans & advances | 3.42 | 0.82 | 0.51 | 0.39 |
| Total current assets | 30.26 | 8.70 | 3.26 | 2.58 |
| Total current liabilities | 2.08 | 1.63 | 1.37 | 1.80 |
| Net working capital | 28.18 | 7.07 | 1.89 | 0.78 |
| Total assets | 39.70 | 8.91 | 3.26 | 2.24 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Opening cash | 0.02 | 0.12 | 0.09 | 0.04 |
| Net cash from operating activities | (9.42) | (2.22) | 0.23 | 0.68 |
| Net cash from investing activities | (14.50) | (0.87) | (0.16) | (0.01) |
| Net cash from financing activities | 25.19 | 2.98 | (0.04) | (0.63) |
| Net change in cash | 1.26 | (0.10) | 0.03 | 0.04 |
| Closing cash | 9.74 | 0.02 | 0.12 | 0.09 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Growth | ||||
| Sales growth | +110.0% | +219.4% | +72.8% | - |
| EBITDA growth | +85.2% | +202.4% | +98.4% | - |
| PBT growth | +96.5% | +243.5% | +217.2% | +9997.0% |
| Net income growth | +102.0% | +202.4% | +196.4% | - |
| Revenue CAGR (3Y) | +126.3% | - | - | - |
| EBITDA CAGR (3Y) | +123.2% | - | - | - |
| Profitability & leverage | ||||
| Net income margin | +15.1% | +15.7% | +16.6% | +9.7% |
| Return on capital employed | +27.7% | +57.6% | +41.2% | +20.6% |
| Return on net worth | +25.0% | +81.6% | +113.9% | +77.8% |
| Debt / equity | 0.20 | 0.98 | 3.09 | 7.58 |
| Long-term debt / equity | 0.15 | 0.48 | 1.40 | 5.26 |
| Interest cover | 7.99 | 10.00 | 24.74 | 61.29 |
| Efficiency & per share | ||||
| Fixed asset turnover | 11.91 | 6.65 | 2.51 | 1.47 |
| Inventory turnover | 4.95 | 4.59 | 2.72 | 2.23 |
| Debtors turnover | 5.91 | 9.09 | 9.54 | 3.63 |
| EPS (₹) | 7.00 | 51.35 | 22.83 | 7.79 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 49.00 | 103.74 | 30.14 | 7.31 |
To see the full year-wise statements and ratios of Accretion Nutraveda Limited, buy the company report.
Board of directors and KMP of Accretion Nutraveda Limited
Accretion Nutraveda Limited currently reports 8 directors and 1 key managerial person. 6 former directors have served the organization.
Current Directors and KMP
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Hardik Mukundbhai Prajapati | Director | 16 Mar 2021 | 5 Years 7 Months | Current |
| Harshad Nanubhai Rathod Also directs: Accretion Pharmaceuticals Limited | Director | 16 Mar 2021 | 5 Years 7 Months | Current |
| Mayur Popatlal Sojitra | Managing Director | 16 Mar 2021 | 5 Years 7 Months | Current |
| Shruti Gupta | Director | 11 Sep 2025 | 1 Years 1 Months | Current |
| Mahipal Singh Chouhan | Director | 11 Sep 2025 | 1 Years 1 Months | Current |
| Arun Dash Also directs: Weldor CNC Machines Limited, Arjun Jewellers Limited, Dash Dwivedi & Associates LLP and 1 more | Director | 11 Sep 2025 | 1 Years 1 Months | Current |
Showing 6 of 9 current directors and KMP. View all directors and KMP
Charges & borrowings
Open charges
₹3.46 Cr
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 31 May 2021 | 100457709 | Indian Bank | ₹3.46 Cr | Open |
To see the full charge records of Accretion Nutraveda Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Accretion Nutraveda Limited has 6 deals on record (5 market trades, 1 ipo); the latest was in September 2026.
Total deals
6
Market trades
5
IPO
1
Deals on record (5 of 6)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2026 | Market trade | ₹1.84 Cr | Buyer: Namamikashi Hotel Private Limited Seller: Lakshmishree Investment and Securities Limited |
| Jul 2026 | Market trade | ₹2.5 Cr | Buyer: Trade Pulse Broking Private Limited |
| Feb 2026 | Market trade | ₹6.05 Cr | Seller: Radiant Global Fund-Class B Participating Shares |
| Feb 2026 | Market trade | ₹1.4 Cr | Buyer: Sunflower Broking Private Limited Seller: Sunflower Broking Private Limited |
| Feb 2026 | Market trade | ₹1.8 Cr | Buyer: an individual |
To see the full deal history of Accretion Nutraveda Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Accretion Nutraveda Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Accretion Nutraveda Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Accretion Nutraveda has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAUCA9884F1Z0 | Gujarat | Active | 18 Apr 2021 |
To see the full GST registrations and return filing status of Accretion Nutraveda Limited, buy the company report.
Recent activity
Accretion Nutraveda Limited has 15 board changes on record since 2021: 9 appointments and 6 cessations. The latest: Arun Dash was appointed as Director on 11 Sep 2025.
Filing
Accretion Nutraveda Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
AGM
Accretion Nutraveda Limited last Annual general meeting of members was held on 11 Sep 2025 as per latest MCA records.
Appointed
Arun Dash was appointed as Director.
Appointed
Mahipal Singh Chouhan was appointed as Director.
Appointed
Paraskumar Vinubhai Parmar was appointed as CFO.
Appointed
Shruti Gupta was appointed as Director.
Ceased
Hardik Mukundbhai Prajapati ceased to be Director.
Ceased
Harshad Nanubhai Rathod ceased to be Director.
Ceased
Mayur Popatlal Sojitra ceased to be Director.
Ceased
Paraskumar Vinubhai Parmar ceased to be Additional Director.
Charges
A charge with Indian Bank of Rs. 3.46 Cr registered on 31 May 2021 with Charge ID 100457709 was modified on 02 Sep 2025.
Ceased
Ankurkumar Shantilal Patel ceased to be Additional Director.
8 earlier events are in the company report.
News
Frequently asked questions
Accretion Nutraveda is an active public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 16 March 2021 (5+ years old) and is registered under CIN U24290GJ2021PLC121216. Listed on BSE: 544694.
Accretion Nutraveda reported revenue of ₹33.6 Cr for FY 2025-26 (up 110% YoY) based on standalone financials.
Accretion Nutraveda has 9 current directors and KMP:
- Mayur Popatlal Sojitra - Managing Director
- Ankurkumar Shantilal Patel - Whole-Time Director
- Hardik Mukundbhai Prajapati - Director
- Harshad Nanubhai Rathod - Director
- Shruti Gupta - Director
- Mahipal Singh Chouhan - Director
- Arun Dash - Director
- Vivek Ashok Kumar Patel - Director
- Paraskumar Vinubhai Parmar - Cfo
The latest financial statements of Accretion Nutraveda on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 11 September 2025. Year-wise statements from FY 2021 are in the company report.
The GSTIN of Accretion Nutraveda is 24AAUCA9884F1Z0, registered in Gujarat.
The CIN (Corporate Identification Number) of Accretion Nutraveda is U24290GJ2021PLC121216. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Accretion Nutraveda is a listed company as per MCA records. Its shares are listed on BSE (code: 544694).
Accretion Nutraveda was incorporated on 16 March 2021, making it 5+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Accretion Nutraveda has 6 deals on record (5 market trades, 1 ipo); the latest was in September 2026.
Arun Dash was appointed as Director on 11 Sep 2025. Mahipal Singh Chouhan was appointed as Director on 11 Sep 2025. Paraskumar Vinubhai Parmar was appointed as CFO on 11 Sep 2025. Accretion Nutraveda has 15 board changes on record in total.